Assignee
EPICENTRX INC
US·27 granted patents·22 pending applications·130 citations·filing 2014–2025
Top patents by PatentIndex Score
49 records- 0197US9987270B1Treatment of gliomas using organonitro compound combination therapyEPICENTRX INC·Filed 2016·Granted Jun 5, 2018·16 cites·35 claims
- 0296US9468625B2Organonitro thioether compounds and medical uses thereofEPICENTRX INC·Filed 2015·Granted Oct 18, 2016·15 cites·20 claims
- 0394US11925617B2Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereofEPICENTRX INC·Filed 2021·Granted Mar 12, 2024·2 cites·22 claims
- 0494US11701351B2Treatment of gliomas using organonitro compound combination therapyEPICENTRX INC·Filed 2021·Granted Jul 18, 2023·2 cites·20 claims
- 0594US10149832B2Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereofEPICENTRX INC·Filed 2015·Granted Dec 11, 2018·12 cites·24 claims
- 0694US9226915B2Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereofEPICENTRX INC·Filed 2014·Granted Jan 5, 2016·16 cites·37 claims
- 0793US11008287B2Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicineEPICENTRX INC·Filed 2017·Granted May 18, 2021·9 cites·19 claims
- 0892US10543208B2Treatment of gliomas using organonitro compound combination therapyEPICENTRX INC·Filed 2018·Granted Jan 28, 2020·12 cites·12 claims
- 0991US10342778B1Treatment of brain metastases using organonitro compound combination therapyEPICENTRX INC·Filed 2016·Granted Jul 9, 2019·13 cites·30 claims
- 1089US11576895B2Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanoneEPICENTRX INC·Filed 2017·Granted Feb 14, 2023·4 cites·19 claims
- 1188US12109348B2Medication infusion devices, systems, and methodsEPICENTRX INC·Filed 2020·Granted Oct 8, 2024·2 cites·23 claims
- 1288US11510901B2Methods and compositions utilizing RRx-001 combination therapy for radioprotectionEPICENTRX INC·Filed 2019·Granted Nov 29, 2022·7 cites·20 claims
- 1388US11160784B1Treatment of brain metastases using organonitro compound combination therapyEPICENTRX INC·Filed 2019·Granted Nov 2, 2021·8 cites·19 claims
- 1488US10906957B2Immunomodulatory fusion proteinsEPICENTRX INC·Filed 2017·Granted Feb 2, 2021·2 cites·8 claims
- 1587US11744859B2Compositions and methods for parenteral administration of therapeutic agentsEPICENTRX INC·Filed 2018·Granted Sep 5, 2023·2 cites·21 claims
- 1686US11660286B2Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood productsEPICENTRX INC·Filed 2019·Granted May 30, 2023·3 cites·6 claims
- 1786US11253608B2Recombinant adenoviruses carrying transgenesEPICENTRX INC·Filed 2018·Granted Feb 22, 2022·2 cites·24 claims
- 1884US12291726B2A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoterEPICENTRX INC·Filed 2024·Granted May 6, 2025·0 cites·19 claims
- 1984US2025074967A1Immunomodulatory fusion proteinsEPICENTRX INC·Filed 2024·Application pending·0 cites
- 2080US12357607B2Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanoneEPICENTRX INC·Filed 2022·Granted Jul 15, 2025·0 cites·37 claims
- 2179US11834492B2Human IL-10 receptor alpha fusion proteinsEPICENTRX INC·Filed 2018·Granted Dec 5, 2023·1 cites·11 claims
- 2277US12357608B2Methods and compositions utilizing RRx-001 combination therapy for radioprotectionEPICENTRX INC·Filed 2023·Granted Jul 15, 2025·0 cites·41 claims
- 2375US2026097013A1Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanoneEPICENTRX INC·Filed 2025·Application pending·0 cites
- 2475US2024052016A1Human il-10 receptor alpha fusion proteinsEPICENTRX INC·Filed 2023·Application pending·0 cites
- 2574US12048793B2Medication infusion devices, systems, and methodsEPICENTRX INC·Filed 2019·Granted Jul 30, 2024·2 cites·8 claims
- 2674US2024122977A1Compositions and methods for parenteral administration of therapeutic agentsEPICENTRX INC·Filed 2023·Application pending·0 cites
- 2773US12280123B2Recombinant adenoviruses carrying transgenesEPICENTRX INC·Filed 2022·Granted Apr 22, 2025·0 cites·17 claims
- 2873US2024374562A1Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood productsEPICENTRX INC·Filed 2023·Application pending·0 cites
- 2971US12054530B2Immunomodulatory fusion proteinsEPICENTRX INC·Filed 2021·Granted Aug 6, 2024·0 cites·14 claims
- 3071US2025099666A1Medication infusion devices, systems, and methodsEPICENTRX INC·Filed 2024·Application pending·0 cites
- 3171US2025161548A1Medication infusion devices, systems, and methodsEPICENTRX INC·Filed 2024·Application pending·0 cites
- 3271US2020046682A1Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereofEPICENTRX INC·Filed 2019·Application pending·0 cites
- 3366US2018085346A1Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereofEPICENTRX INC·Filed 2017·Application pending·0 cites
- 3463US11999973B2Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoterEPICENTRX INC·Filed 2018·Granted Jun 4, 2024·0 cites·23 claims
- 3563US2025288555A1Systems and methods to improve exercise toleranceEPICENTRX INC·Filed 2023·Application pending·0 cites
- 3663US2025388930A1Tumor selective tata-box and caat-box mutantsEPICENTRX INC·Filed 2025·Application pending·0 cites
- 3762US2020375982A1Treatment of gliomas using organonitro compound combination therapyEPICENTRX INC·Filed 2019·Application pending·0 cites
- 3862US2026035346A1Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methodsEPICENTRX INC·Filed 2023·Application pending·0 cites
- 3961US2025134858A1Compositions and methods for treatment of nafld and nash and related dyslipidemiasEPICENTRX INC·Filed 2023·Application pending·0 cites
- 4060US2024293360A1Crystalline abdnaz compositions and methods of making and using the sameEPICENTRX INC·Filed 2022·Application pending·0 cites
- 4159US2024382451A1Organonitro and sulfoxyalkyl organonitro compounds for use in treating medical disordersEPICENTRX INC·Filed 2022·Application pending·0 cites
- 4257US2023235355A1Mono- and multi-valent sars-cov- 2 adenoviral vector vaccines and sars-cov-2 immune globulin and methods of useEPICENTRX INC·Filed 2021·Application pending·0 cites
- 4353US12295976B2Personalized cancer vaccinesEPICENTRX INC·Filed 2019·Granted May 13, 2025·0 cites·19 claims
- 4453US12036247B2Multiple transgene recombinant adenovirusEPICENTRX INC·Filed 2018·Granted Jul 16, 2024·0 cites·13 claims
- 4549US2019352669A1Tumor selective tata-box and caat-box mutantsEPICENTRX INC·Filed 2018·Application pending·0 cites
- 4647US2020155625A1Anti-angiogenic adenovirusEPICENTRX INC·Filed 2018·Application pending·0 cites
- 4746US2020345689A1METHODS AND COMPOSITIONS UTILIZING RRx-001 FOR RADIOPROTECTIONEPICENTRX INC·Filed 2019·Application pending·0 cites
- 4844US2019352616A1Multiple transgene recombinant adenovirusEPICENTRX INC·Filed 2018·Application pending·0 cites
- 4940US2016331771A1Treatment of Hyperproliferative Disorders Using Cardiac GlycosidesEPICENTRX INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EPICENTRX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →